Lloyd’s Market Association names new regulatory affairs head

-



The Lloyd’s Market Association (LMA), which offers professional and technical support to the Lloyd’s underwriting community, has named John Levett as the head of regulatory affairs.

Reporting to LMA legal director Arabella Ramage, Levett’s new role will see him continue the work he began in October 2023, when he joined the association as senior executive, regulatory affairs.

Levett assumes the new role immediately.


His experience includes a stint at RSA Insurance as senior regulatory lead and a five-year term at the FCA as a technical specialist in general insurance compliance.

In addition, his expertise in product governance-related thematics and his leadership of the LMA committee for environmental and climate litigation will be instrumental in his new position.

Levett said: “I am delighted to be taking up this role at such an important time for our industry and our members. Smarter regulation can only help reinforce the London market’s global reputation as the centre of insurance and reinsurance technical expertise.”

Event : International Top Pharmaceutical Awards 


For Enquiries : pharmaquerys123@gmail.com 

Get Connected Here 
 --------------------------------- 
 ---------------------------------  
Twitter: x.com/TopPharmaaward  

Comments

Post a Comment

Popular posts from this blog

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024

-
Image
New safety information for healthcare professionals Veoza (fezolinetant): new recommendations to minimise risk of liver injury The PRAC has agreed to a direct healthcare professional communication (DHPC) informing of the risk of drug-induced liver injury (DILI) with Veoza (fezolinetant) and has recommended monitoring of liver function before and during treatment. Veoza is a medicine used to treat moderate-to-severe vasomotor symptoms (also referred to as hot flushes or night sweats) associated with menopause. The committee considered a review of the potential risk of fezolinetant to cause drug-induced liver injury based on information from all available sources, including reports of suspected side effectsand studies published in the scientific literature. Severe elevations of the liver enzymes alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (>10x upper limit of normal) with concurrent elevations in bilirubin and/or alkaline phosphatase (ALP) have been reporte...
Read more

Cell therapy weekly: partnerships for advancing cell and gene therapies

-
Image
This week: Partnerships to advance cell and gene therapies have been announced, focusing on three key areas: developing gene therapies, enhancing cell and gene therapy manufacturing and developing treatments for difficult-to-treat conditions. The news highlights:Centers of excellence for gene therapy research Advancing cell and gene therapy manufacturing Developing therapies for difficult-to-treat conditions Centers of excellence for gene therapy research The Medical Research Centre (MRC), part of UK Research and Innovation (UKRI; both Swindon, UK) is establishing two Centers of Research Excellence (CoRE) to advance therapies for untreatable diseases, each receiving up to roughly US$64 million over 14 years aiming to transform treatments for diseases such as heart disease, immune disorders and neurodegenerative diseases like Huntington’s disease. Oxford University (UK) will lead the MRC/BHF CoRE in Advanced Cardiac Therapies, which will be co-funded with the British Heart Foundati...
Read more